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Naphazoline is a peripheral 𝛼
2
-adrenergic receptor agonist commonly used as a topical decongestant. In Japan, over-the-
counter antiseptics often contain naphazoline to effect local hemostasis. We present the first case involving the development of
hypercoagulopathy, with kidney and liver dysfunction, following a naphazoline overdose. A 22-year-old Japanese woman with
a history of depression ingested 160mL of a commercially available antiseptic containing 0.1% naphazoline. Three days later,
she was brought to the emergency department because of general fatigue, nausea, and vomiting. Physical examination revealed
cool, pale extremities. Laboratory data showed evidence of severe kidney and liver dysfunction (creatinine, 9.2mg/dL; alanine
aminotransferase, 2948 IU/L), hypercoagulation (D-dimers, 58.3 𝜇g/mL), and thrombocytopenia (platelet count, 90,000/𝜇L).
After infusion of normal saline, intravenous administration of alprostadil, and hemodiafiltration, her organ function completely
recovered. Because both the kidney and liver express 𝛼
2
-adrenergic receptors, their failure was likely associated with naphazoline
overdose-induced hypoperfusion. The most plausible causes of hypercoagulation are peripheral low perfusion and subsequent
microthrombus formation. This case illustrates that severe organ dysfunction can occur following over-the-counter antiseptic
ingestion and serves as a caution for both drug manufacturers and healthcare professionals.
1. Introduction
Naphazoline is commonly used as a topical nasal and ocular
decongestant, and its therapeutic effect results from stim-
ulation of peripheral postsynaptic 𝛼
2
-adrenergic receptors.
Similar to dexmedetomidine and clonidine, naphazoline also
acts as an 𝛼
2
-adrenergic receptor agonist in the central
nervous system. As summarized in Table 1, the most com-
mon symptoms of naphazoline overdose include conscious-
ness disturbances, bradycardia, bradypnea, transitory arterial
hypertension, miosis, and diaphoresis [1–11]. Even severe
hypertension, afterloadmismatch, and pulmonary edema can
result from ingestion of a copious amount of naphazoline
[3, 8–10]. In Japan, over-the-counter antiseptics, which often
contain naphazoline to effect local hemostasis, are widely
available.
Liver and kidney dysfunction following naphazoline
overdose is rare [10, 11], and the etiology of naphazoline-
induced organ disorders is unclear. Moreover, no previous
report has described the development of hypercoagulopathy
after naphazoline ingestion.
We describe a patient who developed hypercoagulopathy
with kidney and liver dysfunction following ingestion of a
naphazoline-containing antiseptic. The patient’s symptoms
were likely associated with systemic vasoconstriction and low
organ and peripheral perfusion arising from the pharmaco-
logical properties of an 𝛼
2
-adrenergic receptor agonist.
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2. Case Presentation
A 22-year-old Japanese woman with a 2-year history of
depression attempted suicide by ingesting 160mL of a com-
mercially available antiseptic containing 0.1% naphazoline,
0.1% benzalkonium chloride, 0.1% chlorpheniramine, and
1.0% lidocaine.Three days later, she was brought to the emer-
gency department (ED) because of general fatigue, nausea,
and vomiting. According to her family, she had been able
to take in food and water during the days before admission.
Her initial vital signs recorded in the ED were as follows:
body temperature, 37.3∘C; heart rate, 54 beats per min; blood
pressure, 109/87mmHg; and respiratory rate, 20 breaths per
min. She was oriented (Glasgow Coma Scale score of 15) but
slightly agitated. Her peripheral extremities were cold, dry,
and pale, and her capillary refill time was prolonged (>4 s).
Her medications at the time of admission were duloxetine,
aripiprazole, lorazepam, brotizolam, and flunitrazepam. She
denied overdose of these medications or illicit drugs.
Laboratory data on admission revealed severe kidney and
liver dysfunction (blood urea nitrogen, 77mg/dL; creatinine,
9.2mg/dL; alanine aminotransferase, 2948 IU/L; aspartate
aminotransferase, 265 IU/L), hypercoagulation (D-dimers,
58.3 𝜇g/mL; fibrin degradation products, 98.0 𝜇g/mL), pro-
longation of prothrombin time (percentage of standard value,
65.3%), and thrombocytopenia (platelet count, 90,000/𝜇L).
Plasma fibrinogen (180mg/mL) and serum albumin
(2.9 g/dL) levels were at the lower limit of the normal ranges,
and creatine kinase (80 IU/L) and total bilirubin (0.9mg/dL)
concentrations were within normal limits. There was no
evidence of hemoconcentration (hemoglobin, 11.7 g/dL;
hematocrit, 34.7%; Na+, 135mEq/L; and K+, 4.2mEq/L).
Computed tomography showed bilateral renal swelling,
suggesting acute renal failure. The inferior vena cava was
not collapsed on computed tomography or ultrasonography.
There was no evidence of deep vein thrombosis, pulmonary
thromboembolism, or crush syndrome.The patient’s electro-
cardiogram was unremarkable other than sinus bradycardia.
The direct causation, ingestion of a naphazoline-contain-
ing antiseptic, evidence of low peripheral perfusion, and
bradycardia were consistent with naphazoline intoxication.
Because naphazoline is a strong agonist of peripheral 𝛼
2
-
adrenergic receptors, hypercoagulopathy may result from
peripheral vasoconstriction, hypoperfusion, and subsequent
hypercoagulation andmicrothrombus formation.The kidney
and liver failures were likely associated with systemic vaso-
constriction and decreased blood flow to the organs.
Because of the patient’s diaphoresis, nausea, and vom-
iting, the differential diagnosis of tissue hypoperfusion and
kidney and liver dysfunction was dehydration. However,
there was neither hemoconcentration nor inferior vena cava
collapse at the time of admission. These findings made
dehydration-induced organ failure less likely.
The patient was treated with a transfusion of normal
saline (3000mL/day) and a 10-𝜇g intravenous bolus of
alprostadil (Palux Injection; Taisho Pharmaceutical Co.,
Tokyo, Japan), a synthetic variant of prostaglandin E1, daily
for 7 days. On day 2, the patient remained anuric and was
therefore treated with hemodiafiltration. Her urine produc-
tion returned by day 3; this was followed by development of
the diuretic phase and complete recovery. The hypercoagu-
lopathy and liver dysfunction also gradually resolved.
After further psychiatric evaluation and inpatient treat-
ment, the patient was discharged home, where she returned
to her normal activities. At her outpatient follow-up visit 1
month later, kidney function and liver function were normal.
3. Discussion
This case involved kidney and liver dysfunction arising from
overdose of an antiseptic containing an 𝛼
2
-adrenergic recep-
tor agonist. The kidney and liver are especially vulnerable
to prolonged low perfusion because both require high blood
flow relative to organ mass. The patient’s hypercoagulation is
likely explained by peripheral hypoperfusion and subsequent
microthrombus formation. Her liver dysfunction may also
have exacerbated the hypercoagulation by impairing clear-
ance of clotting factors.
The liver and kidney receive abundant blood flow relative
to organ mass. Therefore, both of these organs may be
predisposed to low perfusion arising from ingestion of a
copious amount of naphazoline. In addition, microthrombi
may aggravate these organs’ dysfunction and vice versa. In
humans, both the renal cortex and hepatic vessels express 𝛼
2
-
adrenergic receptors [12, 13]. Talke et al. [14] reported that
cardiac output and renal blood flowweremarkedly decreased
after intravenous administration of a high dose of an 𝛼
2
-
adrenergic agonist in sheep.These experimental findings [12–
14] support the pathogenesis suspected in the present case.
However, kidney failure and liver failure are not typical
of naphazoline intoxication. For example, only two reported
cases involved patients who developed kidney failure fol-
lowing naphazoline ingestion (Table 1) [10, 11]. Also, hyper-
coagulopathy associated with naphazoline ingestion has not
been reported. Our patient presented 72 h after taking 160mg
of naphazoline. This amount is the greatest, and this delay
the longest, reported in the literature (Table 1). In other
patients who developed kidney and liver dysfunction, the
estimated naphazoline intake was also high (150mg) [10, 11],
and initial treatment was delayed for 48 h [11]. Dose and
time dependency may therefore exist between naphazoline
ingestion and the development of severe organ dysfunction.
Rapid restoration of organ blood flow may be vital in the
treatment of naphazoline intoxication.
In addition to naphazoline, the other agents in the
antiseptic ingested by this patient were 0.1% benzalkonium
chloride, 0.1% chlorpheniramine, and 1.0% lidocaine. Typical
symptoms of toxicity associated with these agents do not
explain the liver dysfunction, kidney failure, and hypercoag-
ulopathy observed in the present case. Nevertheless, the anti-
cholinergic property of chlorpheniramine might have weak-
ened the peristalsis of the gastrointestinal tract, enhancing
naphazoline absorption. Benzalkonium chloride is a cationic
surfactant and may therefore have aggravated the patient’s
dehydration and tissue hypoperfusion. Other pharmacologic
components of these agents may have synergized the toxic
effects of naphazoline, leading to severe organ dysfunction.
4 Case Reports in Emergency Medicine
Alprostadil has potent pharmacologic effects, including
vasodilation, inhibition of platelet aggregation, and improve-
ment of microcirculation [15, 16]. Although no prior report
has described the use of intravenous alprostadil for the
treatment of 𝛼
2
-adrenergic receptor agonist overdose, we
selected this agent because prostaglandin E1 has several other
benefits, including hepatic and renal cytoprotection [16–
18], facilitation of liver regeneration [19], and prevention of
further formation ofmicrothrombi [20]. Prostaglandin E1 has
also been found to be useful in treating patients with contrast-
induced nephropathy [16, 21] and fulminant hepatitis [22, 23].
In the present case, plasma and urine concentrations of
naphazoline were not measured because of our limited access
to the required measurement systems and small budget. In
another reported case of a 23-year-old Japanese man who
ingested 150mg of naphazoline 48 h before presentation, the
plasma naphazoline concentration was 1.4 𝜇g/mL [11]. We
speculate that our patient had a higher plasma concentration
because she had ingested 160mg of naphazoline.
In conclusion, we have reported a case involving a patient
who developed hypercoagulation, liver dysfunction, and
renal failure after ingesting a large amount of a naphazoline-
containing antiseptic. The likely pathogenesis in this case
was vasoconstriction, low organ perfusion, and impaired
microcirculation arising from systemic 𝛼
2
-adrenergic recep-
tor stimulation. This case illustrates that severe organ dys-
function can occur following over-the-counter antiseptic
ingestion and serves as a caution for both drugmanufacturers
and healthcare professionals. This case facilitated our under-
standing of the pathophysiology of organ failure following
naphazoline overdose.
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